Lee Financial CO Fibrogen Inc Transaction History

Lee Financial CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 11, 2022	SELL	$12.02 - $16.79 $17,104 - $23,892	-1,423 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$10.18 - $26.64 $16,288 - $42,624	-1,600 Reduced 52.93%	1,423 $14,000
Q2 2021 Aug 04, 2021	SELL	$18.57 - $35.68 $16,713 - $32,112	-900 Reduced 22.94%	3,023 $81,000
Q1 2021 May 13, 2021	SELL	$31.0 - $55.72 $105,400 - $189,448	-3,400 Reduced 46.43%	3,923 $136,000
Q4 2020 Feb 12, 2021	SELL	$37.09 - $48.97 $37 - $48	-1 Reduced 0.01%	7,323 $272,000
Q4 2017 Feb 09, 2018	BUY	$41.95 - $60.1 $307,241 - $440,172	7,324	7,324 $347,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Lee Financial CO, based on Form 13F filings with the SEC.

Stay updated on Lee Financial CO with notifications on news.